Astellas taps proteostasis in potential $1.2bn alliance
This article was originally published in Scrip
Executive Summary
Assuming all milestones are met and options exercised, a new deal with Japan's Astellas will provide a bonanza for Proteostasis, being worth potentially more than $1.2bn to the privately-held US drug discovery venture.